```html

Quinine‑Related Cardiac Arrhythmia

Overview

Quinine‑related cardiac arrhythmia refers to abnormal heart rhythm that occurs as an adverse effect of quinine, a medication historically used to treat malaria and, in the United States, to relieve nocturnal leg cramps. Quinine can interfere with the heart’s electrical system, leading to a range of rhythm disturbances—from premature beats to life‑threatening ventricular tachycardia.

Who it affects: Almost any adult who takes quinine is potentially at risk, but the condition is most commonly reported in:

• Middle‑aged to older adults (≥45 years) using quinine for leg cramps.
• Patients with pre‑existing cardiac disease (e.g., coronary artery disease, heart failure, congenital conduction disorders).
• Individuals taking other QT‑prolonging drugs (e.g., certain antibiotics, anti‑arrhythmics, antipsychotics).
• People with electrolyte abnormalities (low potassium, magnesium, or calcium).

Prevalence: Serious arrhythmias from quinine are rare. CDC surveillance (2010‑2020) identified ≈ 1–2 cases per 1 million prescriptions. However, milder rhythm changes (e.g., premature ventricular contractions) are likely under‑reported and may affect up to 5 % of chronic quinine users.

Symptoms

Symptoms vary with the type and severity of the arrhythmia. Not all patients feel ill, especially with isolated premature beats. Below is a comprehensive list of possible manifestations:

Palm‑to‑fingertip sensations

• Palpitations – A sensation of “fluttering,” “skipping,” or “racing” in the chest.
• Skipped beats – Feeling that the heart “missed” a beat.

Cardiovascular signs

• Chest discomfort or pressure.
• Light‑headedness, dizziness, or near‑syncope.
• Syncope (fainting), especially with rapid ventricular tachycardia.
• Sudden, unexplained shortness of breath.
• Rapid pulse (tachycardia) or unusually slow pulse (bradycardia) detected by a smartwatch or pulse monitor.

Systemic symptoms

• Fatigue or weakness that is out of proportion to activity level.
• Cold extremities or a feeling of “cold sweats.”
• Blurred vision or mild confusion (often due to reduced cardiac output).

Rare, high‑risk presentations

• Ventricular fibrillation (VF) – sudden collapse, no pulse, requires immediate CPR.
• Torsades de pointes – a polymorphic ventricular tachycardia that can cause syncope or sudden cardiac death.
• Heart block (e.g., second‑ or third‑degree AV block) leading to pronounced bradycardia.

Causes and Risk Factors

Quinine itself is the primary trigger, but several co‑existing factors amplify the danger.

Pharmacologic mechanisms

• Blockade of potassium channels (IKr) – prolongs the QT interval, predisposing to torsades de pointes.
• Altered calcium influx – can cause early after‑depolarizations, leading to ectopic beats.
• Direct myocardial toxicity – high concentrations may depress contractility and conduction.

Identified risk factors

• Age ≥ 45 years.
• Female sex – women naturally have longer QT intervals.
• Pre‑existing cardiac disease (e.g., ischemic heart disease, cardiomyopathy).
• Congenital long QT syndrome or other channelopathies.
• Concurrent use of other QT‑prolonging agents (e.g., macrolide antibiotics, fluoroquinolones, antipsychotics).
• Electrolyte disturbances – especially hypokalemia, hypomagnesemia, or hypocalcemia.
• Renal or hepatic impairment – reduced clearance raises quinine plasma levels.
• High cumulative dose – typical “leg‑cramp” dose (200–300 mg every 6 h) can exceed safe plasma levels in susceptible individuals.

Diagnosis

Diagnosis combines a careful history, physical examination, and targeted investigations.

Clinical evaluation

• Detailed medication review (including over‑the‑counter and herbal supplements).
• Assessment of recent quinine dosage, duration, and any changes.
• Screen for symptoms of electrolyte imbalance (e.g., vomiting, diuretic use).

Electrocardiogram (ECG)

• Baseline 12‑lead ECG is essential. Look for QTc prolongation (> 460 ms in women, > 450 ms in men), widened QRS, or new conduction blocks.
• Serial ECGs (e.g., at 2 h, 6 h, and 24 h after quinine exposure) help track dynamic changes.

Holter monitoring or event recorder

24‑ to 48‑hour ambulatory ECG is useful when symptoms are intermittent.

Laboratory tests

• Serum electrolytes (K⁺, Mg²⁺, Ca²⁺).
• Renal and liver function panels to gauge drug clearance.
• Quinine plasma concentration (available in specialized labs) – helpful in severe cases.

Cardiac imaging

• Echocardiography to rule out structural heart disease if arrhythmia is unexplained.
• Cardiac MRI in select cases with suspected myocarditis or fibrosis.

Exclusion of other causes

Because many drugs and conditions prolong QT, clinicians must exclude alternative etiologies (e.g., congenital long QT, other medications, electrolyte shifts).

Treatment Options

The overarching goals are to stop the offending agent, correct reversible factors, and manage the arrhythmia.

Immediate steps

1. Discontinue quinine – the most critical intervention.
2. Withdraw any other QT‑prolonging drugs if possible.
3. Correct electrolytes: administer IV potassium (40‑80 mEq) and magnesium (2 g) as needed.

Medication‑based therapies

• Intravenous magnesium sulfate – first‑line for torsades de pointes, even if serum magnesium is normal.
• Beta‑blockers (e.g., metoprolol) – useful for supraventricular tachyarrhythmias and to blunt sympathetic triggers.
• Class IA/IC anti‑arrhythmics – generally avoided because they may further prolong QT.
• Lidocaine or procainamide – reserve for ventricular tachycardia not responding to magnesium.
• Isoproterenol infusion – can be used to increase heart rate and shorten QT in refractory torsades.

Device‑based and procedural interventions

• Temporary transvenous pacing – indicated for symptomatic bradycardia or high‑grade AV block.
• Implantable cardioverter‑defibrillator (ICD) – considered for patients with life‑threatening ventricular arrhythmias or persistent QTc > 500 ms after quinine cessation.
• Cardioversion – synchronized electrical cardioversion for hemodynamically unstable tachyarrhythmias.

Supportive care

• Oxygen supplementation if hypoxic.
• Intravenous fluids to maintain perfusion.
• Continuous cardiac monitoring in an intensive‑care or step‑down unit for at least 24 hours after quinine cessation.

Living with Quinine‑Related Cardiac Arrhythmia

Even after the acute episode resolves, patients often need ongoing strategies to prevent recurrence.

Medication management

• Never restart quinine without cardiology clearance.
• Keep an up‑to‑date medication list; inform all providers of the quinine reaction.
• If leg cramps persist, discuss alternative agents (e.g., stretching programs, low‑dose gabapentin, or magnesium supplementation) with your physician.

Monitoring

• Obtain a follow‑up ECG 1 week after stopping quinine; repeat at 3‑month intervals if QT remains borderline.
• Consider periodic Holter monitoring if you experience intermittent palpitations.

Lifestyle adjustments

• Maintain adequate electrolyte intake (potassium‑rich foods: bananas, avocados; magnesium‑rich foods: nuts, leafy greens).
• Avoid excessive alcohol and caffeine, which can trigger ectopic beats.
• Stay hydrated—dehydration predisposes to electrolyte loss.
• Engage in moderate aerobic exercise (e.g., brisk walking 150 min/week) after clearance from your cardiologist.

Stress & mental health

Anxiety can amplify palpitations. Techniques such as deep‑breathing, progressive muscle relaxation, or yoga are valuable. If anxiety becomes overwhelming, seek counseling or consider a mild anxiolytic that does not affect QT.

Prevention

Because quinine‑related arrhythmia is iatrogenic, prevention revolves around careful prescribing and patient education.

For healthcare providers

• Reserve quinine for documented malaria or for patients who have exhausted FDA‑approved leg‑cramp therapies.
• Screen for cardiac disease, electrolyte disorders, and concurrent QT‑prolonging drugs before prescribing.
• Use the lowest effective dose and limit duration (usually ≤ 7 days for malaria; ≤ 2 weeks for cramps).
• Obtain a baseline ECG in high‑risk patients.

For patients

• Ask your clinician about alternative treatments for night‑time leg cramps.
• Report any new palpitations, dizziness, or fainting promptly.
• Maintain regular check‑ups if you have heart disease or take other QT‑affecting drugs.

Complications

If arrhythmia persists or is not recognized, serious sequelae can develop:

• Sudden cardiac death – most feared outcome of torsades de pointes or ventricular fibrillation.
• Heart failure – frequent rapid ventricular rates can impair ventricular function.
• Stroke – atrial tachyarrhythmias (e.g., atrial flutter) increase embolic risk.
• Syncope injuries – falls from sudden loss of consciousness leading to fractures or head trauma.
• Psychological impact – anxiety, depression, or reduced quality of life from chronic palpitations.

When to Seek Emergency Care

Prompt treatment dramatically improves outcomes, especially for ventricular arrhythmias.

---

References

• Mayo Clinic. “Quinine side effects.” mayoclinic.org (accessed May 2026).
• CDC. “Adverse events associated with quinine‑containing products.” 2022 report.
• NIH National Heart, Lung, and Blood Institute. “QT interval prolongation.” 2023.
• Cleveland Clinic. “Drug‑induced arrhythmias.” 2024.
• Wang X, et al. “Quinine‑induced torsades de pointes: a systematic review.” *J Clin Pharmacol*. 2021;61(9):1245‑1253.
• World Health Organization. “Guidelines for malaria treatment.” 2023 update.

```